BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.15) by 2.61 percent. This is a 3.7 percent decrease over losses of $(1.08) per share from the same period last year.
Credit Suisse Maintains Outperform on MercadoLibre, Raises Price Target to $2050
Credit Suisse analyst Stephen Ju maintains MercadoLibre (NASDAQ:MELI) with a Outperform and raises the price target from $1824 to $2050.
